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See Article, pages 658–664Delta hepatitis is still a major global health problem affecting 15–
20 million individuals world-wide [1,2]. The implementation of
vaccine programs against hepatitis B was initially associated with
a decline in hepatitis D virus (HDV) infections in Southern Europe
during the 1980s and 1990s [3,4]. However, several studies pub-
lished over the last few years have shown that the prevalence of
hepatitis delta remains rather high in Europe – in particular in
immigrant populations. Between 8% and 12% of HBsAg-positive
individuals tested anti-HDV positive in France [5], Germany
[6,7], Italy [8–10], the United Kingdom [11], and Turkey [4]. A
common feature of all these studies was that the majority of
HDV-infected individuals were born in highly endemic areas such
as Eastern Turkey, Central Asia, or Africa. HDV is also prevalent in
South America, in particular in the Amazonian region of Western
Brazil [12], and the Western paciﬁc population [13].
Hepatitis D has been considered as the most severe form of
viral hepatitis in humans. As compared to mono-infection with
the hepatitis B virus (HBV), HBV–HDV coinfection is associated
with an accelerated course of ﬁbrosis progression, earlier hepatic
decompensation of cirrhosis, and an increased risk for the
development of hepatocellular carcinoma [1,2]. In a 28-year
long-term follow-up study from Italy, earlier ﬁndings were con-
ﬁrmed as one quarter of patients with hepatitis D developed
hepatocellular carcinoma, and liver failure was the cause of death
for nearly 60% of the patients [14], which is in line with a recent
preliminary report from Germany [15].
Despite continuous interest in the epidemiology and clinical
outcome of hepatitis delta, our knowledge on the pathophysiol-
ogy of liver disease in HDV infection is still rather limited. Several
cross-sectional studies showed that different patterns of viral
dominances can be observed in patients with hepatitis delta
and that HDV infection is frequently associated with suppressed
HBV replication. About 70–90% of HDV-infected patients are
HBeAg negative and HDV seems also to suppress hepatitis C virus
(HCV) replication in triple infected individuals [16–18]. However
and importantly, very few studies did investigate virological pat-
terns over time and determined virological markers longitudi-
nally for several years. In this context the paper by Maria Buti’sJournal of Hepatology 20
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Journal of Hepatology, is of major interest [19]. In a retrospec-
tive-prospective approach, the authors studied samples of HDV-
infected patients over a period of 4–8 years and determined
quantitative levels of HBV DNA, HDV RNA, and HBsAg. Impor-
tantly, and in contrast to conclusions drawn from previous
cross-sectional approaches, the authors demonstrate a high fre-
quency of ﬂuctuating activity of either one or even both viruses
(Fig. 1). Thus, HDV cannot necessarily be considered as the ‘‘dom-
inant” virus based on a single determination. The authors con-
clude that the role of HBV replication for the pathogenesis of
liver disease in hepatitis D should not be underestimated.
Schaper et al. ﬁrst developed a quantitative real-time PCR
assay for HDV RNA. Until recently, few studies quantitated HDV
RNA in patients with hepatitis delta [20]. A possible advantage
of the assay developed by Schaper et al. is that genomic HDV
RNA from an HDV-infected patient was used as a standard
instead of a cloned cDNA. Thus, the reverse transcription step
was appropriately assessed in this study. Unfortunately, a WHO
standard for HDV RNA is still missing which however would be
highly desirable as it is difﬁcult to compare quantitative HDV
RNA results between different laboratories at present. HDV RNA
levels are not associated with grading or staging of liver disease
[21]. Nevertheless, HDV RNA quantiﬁcation may become more
important as viral declines during antiviral treatment are associ-
ated with long-term virological responses, and thus, treatment
duration could be individualized based on HDV RNA kinetics
[22–24]. The genetic variability of HDV has also to be considered
when developing new assays for HDV RNA quantiﬁcation. At least
eight different HDV genotypes have been identiﬁed [25,26] and
assays have rarely been standardized for all the different variants.
However, the HDV genotype was no issue in the study by Schaper
et al. as all subjects were infected with HDV genotype 1 which
could have been expected for European hepatitis D patients [2].
HDV is considered as the dominant virus in HBV–HDV coin-
fection or HBV–HCV–HDV triple infection. Analysing quantitative
data for HDV RNA, Schaper and colleagues identiﬁed HDV as pre-
dominant in about half of the patients only. Thus, HDV may not
generally suppress HBV. Recently, molecular mechanisms have
been proposed to explain how HDV proteins could interfere with
HBV replication. Both the small HDV p24 protein as well as the
large HDV p27 protein may repress the HBV enhancers pIIE110 vol. 52 j 627–629
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Fig. 1. Schematic representation of HBV DNA and HDV RNA patterns over
time observed in the study by Schaper et al. [19]. Three patients showed
persistently high viremia for both viruses (upper left panel) while only 5 patients
(20%) showed an HDV dominance with suppressed HBV replication throughout
follow up (upper right). In eight subjects both viruses ﬂuctuated, either in
alternating (lower left) or in parallel (lower right).
Editorialand pIIE2 and thereby inhibit HBV replication [27]. However, still
up to 30% of hepatitis delta patients are HBeAg positive and also
the present data from Barcelona describe several patients with
high HBV DNA levels of >105 copies/ml despite HDV coinfection
[19]. Moreover, any potential suppressive effect of one virus
above the other was not ﬁxed as several patients showed ﬂuctu-
ating patterns over time. Notably, HBV DNA levels did only
change if also HDV RNA levels ﬂuctuated. However, both alter-
nating and parallel HBV DNA and HDV RNA proﬁles were
observed, thus making a general dominant direct HBV DNA sup-
pression by HDV unlikely. Overall, these data are also in line with
one Italian study that analyzed patients with HBV–HCV coinfec-
tion over time including some individuals who were also anti-
HDV positive [28]. Nevertheless, both studies included in the
end a rather limited number of patients for the various sub-
groups. It is therefore too early to draw ﬁnite conclusions and
more studies are needed to deﬁne the meaning different virolog-
ical proﬁles and dynamics for the long-term outcome of the
patients. For example, it will be important to determine if speciﬁc
ﬂuctuation patterns are associated with an increased risk to
develop clinical endpoints, and to deﬁne which patients most
urgently require antiviral treatment.
Schaper et al. also studied quantitative HBsAg levels over
time. HBsAg levels do signiﬁcantly differ between different
phases of HBV infection [29], and are usually high in hepatitis
delta despite suppressed HBV DNA [18]. HBsAg levels correlated
with HDV RNA levels in various cross-sectional studies
[21,30,31]. However, longitudinal testing of both parameters in
the present study did not reveal parallel ﬂuctuations of HDV
RNA and HBsAg in all cases. One has to consider that HBsAg pro-
duction and HBV DNA replication are disconnected in later
phases of infection, which could be due, in part, to integration
of HBV into the host genome; potentially providing a separate
template for HBsAg production or cytokine dependent modiﬁca-
tion of viral replication pathways [32]. All these factors could also
play a role in HBV–HDV coinfection, and thus, short-term628 Journal of Hepatology 201changes in HDV RNA viremia may not necessarily parallel with
changes in HBsAg levels.
What are the main clinical consequences of the study by
Schaper et al. for the management and treatment of hepatitis
delta patients? (i) Most importantly hepatitis delta has to be
considered as a highly dynamic disease which is for example
in contrast to chronic hepatitis C. Treatment decisions should
not be based on single determinations of virological parame-
ters, and patients should be advised to consult their doctors
on regular basis, e.g. every 3–6 months. (ii) The role of HBV
for disease progression in delta hepatitis should not be under-
estimated. Thus, although nucleoside and nucleotide analogues
currently approved for the treatment of HBV infection are not
effective against HDV [33], treatment of HBV infection should
not be forgotten in hepatitis delta if indicated according to cur-
rent guidelines [34]. However, HBV resistance should be
avoided as treatment-induced HBV polymerase variants may
also confer changes in the structure of the HBsAg, as the open
reading frames for HBV polymerase and HBsAg overlap. There
is some evidence that the lamivudine-induced sW196S HBsAg
variant inhibits secretion of HDV particles [35,36] with yet
unknown clinical consequences. (iii) Treatment options for
patients with hepatitis delta need to be improved as this com-
plex disease is associated with signiﬁcant morbidity and mor-
tality. Currently, only interferon alpha is effective against
HDV and, as treatment can be complicated in advanced disease,
early treatment might be considered. However and most
importantly, the study by Schaper et al. can only represent
the starting point of investigating the complex nature of viro-
logical patterns in hepatitis delta in more detail. Combined
efforts by various centers are needed to deﬁne distinct clinical
courses which may require more aggressive treatment inter-
ventions and monitoring strategies. We have just started to
understand the complex biology of this very interesting virus
– more than 30 years after its discovery!
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